Inactivation of AKT induces cellular senescence in uterine leiomyoma

Endocrinology

Volumn 155, Issue 4, 2014, Pages 1510-1519

  Xu, Xiaofei ^a,b   Lu, Zhenxiao ^a   Qiang, Wenan ^a   Vidimar, Vania ^a   Kong, Beihua ^b   Kim, J Julie ^a   Wei, Jian Jun ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ACETYLCYSTEINE; APITOLISIB; BETA GALACTOSIDASE; DACTOLISIB; DOXORUBICIN; HYDROETHIDINE; MICRORNA 182; PROTEIN KINASE B; PROTEIN P16; PROTEIN P21; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA;

ARTICLE; CELL AGING; CELL DEATH; CELL STRESS; CONTROLLED STUDY; DRUG MEGADOSE; ENZYME INACTIVATION; ENZYME INHIBITION; FEMALE; GENETIC TRANSFECTION; HETEROCHROMATIN; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; LEIOMYOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; SENESCENCE; UPREGULATION; UTERUS MYOMA;

BETA-GALACTOSIDASE; CELL AGING; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROCYCLIC COMPOUNDS, 3-RING; HMGA2 PROTEIN; HUMANS; LEIOMYOMA; MICRORNAS; MYOMETRIUM; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; UP-REGULATION; UTERINE NEOPLASMS;

EID: 84897825250     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1929     Document Type: Article

References (37)

1. Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188:100-107. (Pubitemid 36135604)
2. Bulun SE. Uterine fibroids. N Engl J Med. 2013;369:1344-1355.
3. Friedman AJ, Daly M, Juneau-Norcross M, Gleason R, Rein MS, LeBoff M. Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin 'add-back' for 2 years. Hum Reprod. 1994;9:1618-1625. (Pubitemid 24291072)
4. American College of Obstetricians and Gynecologists. ACOG practice bulletin. Alternatives to hysterectomy in the management of leiomyomas. Obstet Gynecol. 2008;112:387-400.
5. Peng L, Wen Y, Han Y, et al. Expression of insulin-like growth factors (IGFs) and IGF signaling: molecular complexity in uterine leiomyomas. Fertil Steril. 2009;91:2664-2675.
6. Kovács KA, Lengyel F, Környei JL, et al. Differential expression of Akt/protein kinase B, Bcl-2 and Bax proteins in human leiomyoma and myometrium. J Steroid Biochem Mol Biol. 2003;87:233-240. (Pubitemid 38036957)
7. Yu KR, Park SB, Jung JW, et al. HMGA2 regulates the in vitro aging and proliferation of human umbilical cord blood-derived stromal cells through the mTOR/p70S6K signaling pathway. Stem Cell Res. 2013;10:156-165.
8. Varghese BV, Koohestani F, McWilliams M, et al. Loss of the repressor REST in uterine fibroids promotes aberrant G protein-coupled receptor 10 expression and activates mammalian target of rapamycin pathway. Proc Natl Acad Sci USA. 2013;110:2187-2192.
9. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999;13:2905-2927.
10. Crabtree JS, Jelinsky SA, Harris HA, et al. Comparison of human and rat uterine leiomyomata: identification of a dysregulated mammalian target of rapamycin pathway. Cancer Res. 2009;69:6171-6178.
11. Sefton EC, Qiang W, Serna V, et al. 3 MK-2206, an AKT inhibitor, promotes caspase-independent cell death and inhibits leiomyoma growth. Endocrinology. 2013;154:4046-4059.
12. Meng J, Dai B, Fang B, et al. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PloS One. 2010;5:e14124.
13. Hirai H, Sootome H, Nakatsuru Y, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010;9:1956-1967.
14. Yap TA, Yan L, Patnaik A, et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol. 2011;29:4688-4695.
15. Bononi A, Agnoletto C, De Marchi E, et al. Protein kinases and phosphatases in the control of cell fate. Enzyme Res. 2011;2011:329098.
16. Kennedy AL, Morton JP, Manoharan I, et al. Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol Cell. 2011;42:36-49.
17. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96:857-868. (Pubitemid 29165088)
18. Laser J, Lee P, Wei JJ. Cellular senescence in usual type uterine leiomyoma. Fertil Steril. 2010;93:2020-2026.
19. Wei JJ, Zhang XM, Chiriboga L, Yee H, Perle MA, Mittal K. Spatial differences in biologic activity of large uterine leiomyomata. Fertil Steril. 2006;85:179-187. (Pubitemid 43063443)
20. Wu J, Liu Z, Shao C, et al. HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes. Cancer Res. 2011;71:349-359.
21. Tu Z, Aird KM, Bitler BG, et al. Oncogenic Ras Regulates BRIP1 expression to induce dissociation of BRCA1 from chromatin, inhibit DNA repair, and promote senescence. Dev Cell. 2011;21:1077-1091.
22. Narita M, Narita M, Krizhanovsky V, et al. A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell. 2006;126:503-514. (Pubitemid 44163608)
23. Li G, Luna C, Qiu J, Epstein DL, Gonzalez P. Alterations in microRNA expression in stress-induced cellular senescence. MechAgeing Dev. 2009;130:731-741.
24. Magenta A, Cencioni C, Fasanaro P, et al. miR-200c is up-regulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition. Cell Death Differ. 2011;18:1628-1639.
25. Liu Z, Liu J, Segura MF, et al. MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma. J Pathol. 2012;228:204-215.
26. Moskwa P, Buffa FM, Pan Y, et al. miR-182-mediated down-regulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell. 2011;41:210-220.
27. Zavadil J, Ye H, Liu Z, et al. 2010 Profiling and functional analyses of microRNAs and their target gene products in human uterine leiomyomas. PloS one. 5:e12362.
28. Hodge JC, Kim TM, Dreyfuss JM, et al. Expression profiling of uterine leiomyomata cytogenetic subgroups reveals distinct signatures in matched myometrium: transcriptional profilingof the t(12; 14) and evidence in support of predisposing genetic heterogeneity. Hum Mol Genet. 2012;21:2312-2329.
29. Markowski DN, Helmke BM, Belge G, et al. HMGA2 and p14Arf: major roles in cellular senescence of fibroids and therapeutic implications. Anticancer Res. 2011;31:753-761.
30. Mayer A, Höckel M, Wree A, Leo C, Horn LC, Vaupel P. Lack of hypoxic response in uterine leiomyomas despite severe tissue hypoxia. Cancer Res. 2008;68:4719-4726.
31. Markowski DN, von Ahsen I, Nezhad MH, Wosniok W, Helmke BM, Bullerdiek J. HMGA2 and the p19Arf-TP53-CDKN1A axis: a delicate balance in the growth of uterine leiomyomas. Genes Chromosomes Cancer. 2010;49:661-668.
32. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of microRNA processing by p53. Nature. 2009;460:529-533.
33. Mine N, Kurose K, Nagai H, et al. Gene fusion involving HMGIC is a frequent aberration in uterine leiomyomas. J Hum Genet. 2001;46:408-412. (Pubitemid 32634515)
34. Martin Chaves EB, Brum IS, Stoll J, Capp E, Corleta Hv. Insulin-like growth factor 1 receptor mRNA expression and autophosphorylation in human myometrium and leiomyoma. Gynecol Obstet Invest. 2004;57:210-213. (Pubitemid 38608332)
35. Gao Z, Matsuo H, Wang Y, Nakago S, Maruo T. Up-regulation by IGF-I of proliferating cell nuclear antigen and Bcl-2 protein expression in human uterine leiomyoma cells. J Clin Endocrinol Metab. 2001;86:5593-5599. (Pubitemid 33070293)
36. Peng Y, Laser J, Shi G, et al. Antiproliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma. Mol Cancer Res. 2008;6:663-673. (Pubitemid 351521848)
37. Markowski DN, Winter N, Meyer F, et al. p14Arf acts as an antagonist of HMGA2 in senescence of mesenchymal stem cells-implications for benign tumorigenesis. Genes Chromosomes Cancer. 2011;50:489-498.